Antimicrobial resistance during the COVID-19 pandemic: the missing patient perspective.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
While the use of antibiotics for secondary infections in COVID-19 has been described in scientific literature and guidelines have been issued for their appropriate use, the importance of listening to patients in a systematic manner has often been overlooked. To highlight this issue, we spoke with patients about their experiences with antibiotics as treatment for COVID-19 and their understanding of antimicrobial resistance (AMR). We found that there is a general lack of awareness of the risks of AMR, and even when patients are knowledgeable, fear of COVID-19 and pressure from healthcare providers often override considerations for appropriate use. We present case examples of three patients' experiences and provide recommendations for health systems, healthcare providers, and patients or caregivers on actions they can each take to reduce the risk of AMR during and beyond the COVID-19 pandemic. We also share ways that the patient community can be empowered to provide their voices to decision-making on both COVID-19 treatment protocols and prescriptions of antibiotics.
Identifiants
pubmed: 34192256
doi: 10.1093/jacamr/dlab030
pii: dlab030
pmc: PMC8083678
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
dlab030Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa049
pubmed: 34192248
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa051
pubmed: 34192249